Enanta Pharmaceuticals, Inc. (ENTA) Stock

Enanta Pharmaceuticals, Inc. (ENTA) is a Healthcare stock trading at $12.63 (as of 2026-06-18), with a market capitalization of $382.67M and a trailing P/E of -4.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Enanta Pharmaceuticals, Inc. is a biotechnology company that discovers and develops small-molecule medicines for viral infections and liver diseases. Its research and development programs include targets such as respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus, and it also has a collaboration and licensing arrangement with Abbott Laboratories for hepatitis C virus protease inhibitor compounds.

Valuation — source: SEC EDGAR (first-party)
Price	$12.63
Market Cap	$382.67M
P/E Ratio	-4.9
EV / EBITDA	-6.0
Price / Book	3.16
Price / Sales	5.32
DCF Value (model)	$-17.85
DCF Upside vs Price	-241.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$65.32M
Net Margin	-125.4%
Return on Equity	-53.2%
Current Ratio	3.84
Revenue Growth (YoY)	9.8%
EPS Growth (YoY)	-46.7%
FCF Growth (YoY)	-53.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.11 (distress)

Valuation vs Sector & Industry
Stock P/E	-4.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-123.3%
vs Industry	-128.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock Fund Advisors ($48.48M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jay R. Luly
Employees	131
Country	US
IPO Date	2013-03-21

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.